Ottacef S 250mg/125mg Injection
Marketer
Kestrel Lifesciences
Salt Composition
Ceftriaxone (250mg) + Sulbactam (125mg)
Overview Ottacef S 250mg/125mg Injection
Cefuroxime and Sulbactam injection, 250mg/125mg, is a dual-action antibiotic used to combat diverse bacterial infections. Its mechanism involves inhibiting bacterial growth and halting infection progression. Administration must be under a doctor's direct guidance; consistent adherence to the prescribed schedule is crucial. Completing the full treatment course is vital, even with symptom improvement, as premature cessation can reduce efficacy. Potential side effects include nausea, vomiting, diarrhea, and upset stomach. Severe or worsening side effects necessitate immediate medical attention. Allergic reactions (rash, itching, swelling, breathing difficulties) require prompt emergency care. Inform your physician of all current medications, especially if you are pregnant, breastfeeding, or have any underlying health concerns. Alcohol consumption should be avoided due to the risk of increased drowsiness. While generally safe for driving, refrain from operating vehicles if experiencing drowsiness or dizziness. Adequate rest, a balanced diet, and sufficient hydration contribute to quicker recovery. Monitoring treatment effectiveness may involve periodic lab tests ordered by your doctor.
Uses of Ottacef S 250mg/125mg Injection
Infections caused by bacteria
Major Benefits of Ottacef S 250mg/125mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Ottacef S 250mg/125mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Ottacef S 250mg/125mg Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
How Ottacef S 250mg/125mg Injection works:
Ceftriaxone and Sulbactam, combined as Ottacef S 250mg/125mg Injection, deliver a potent antibacterial effect. Ceftriaxone, a cephalosporin antibiotic, disrupts bacterial cell wall synthesis, hindering bacterial survival. Sulbactam's role as a beta-lactamase inhibitor counteracts bacterial resistance mechanisms, thus optimizing Ceftriaxone's efficacy.
SAFETY ADVICE
AlcoholSAFE
Ottacef S 250mg/125mg Injection may be used concurrently with alcohol without adverse reactions.
PregnancySAFE IF PRESCRIBED
The injectable medication Ottacef S 250mg/125mg is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or absent negative impacts on fetal development; however, clinical data in humans are scarce.
Breast feedingCAUTION
Administering Ottacef S 250mg/125mg Injection to breastfeeding mothers requires careful consideration. Discontinue breastfeeding throughout the mother's treatment course and until the medication is fully cleared from her system.
DrivingUNSAFE
The administration of Ottacef S 250mg/125mg Injection could reduce attentiveness, impair vision, and induce drowsiness or dizziness. Driving should be avoided if these effects manifest.
KidneyCONSULT YOUR DOCTOR
Data regarding the use of Ottacef S 250mg/125mg Injection in individuals with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
The injectable formulation of Ottacef S (250mg/125mg) requires careful administration in individuals with severe hepatic impairment; dosage modification may be necessary. Consult a physician for guidance. Dosage alteration for Ottacef S (250mg/125mg) injection is not advised for patients exhibiting mild to moderate liver dysfunction.
What if you forget to take Ottacef S 250mg/125mg Injection :
Should you forget a scheduled dose of Ottacef S 250mg/125mg Injection, seek medical advice.
Facts to Know About Ottacef S 250mg/125mg Injection
| Label | Value |
|---|---|
| Developing Good Habits | No. |
| Treatment Category | Antimicrobial Agents |
3,018 People bought this recently